Abstract: The somatostatin analogue pasireotide is a new type of protein which is the first therapeutic agent targeted to the pituitary. Pasireotide can prevent adrenocorticotropic hormone release and inhibit the growth of tumor cells after coupling with somatostatin receptor of the target cell membranes. Pasireotide have a high binding affinity for most of somatostatin receptor (SSTR) subtypes and in particular for SSTR₅. Pasireotide can paly an important role in the new round of new targets for individualized diagnosis and treatment of tumor through the studies of translational medicine.

Key words: Receptors, somatostatin, Nuclear medicine, Translationsl medicine, Pasireotide